Surmodics’ Serene single-coat solutions

Eden Prairie, Minnesota – Surmodics Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced the launch of a single-coat formulation of its most advanced hydrophilic medical device coating, Serene solutions. Specifically formulated for individual medical device applications, Serene Single-Coat (SC) solutions allow manufacturers to leverage their legacy coating process to apply this surface treatment.

Surmodics’ Serene coatings help device manufacturers meet the challenge of achieving the right balance of lubricity (reduction in friction) and durability for intravascular products. Surmodics continues to lead the way with significant advances in coating formulations, achieving low friction and low-particulate generation with the latest formulation of Serene SC coating, that meet manufacturer’s current processes to accelerate development and meet customer needs.

“With regulatory attention increasingly focused on lowering particulates, we’ve experienced quick adoption of Serene coatings among manufacturers already equipped for a two-coat process,” said Gary Maharaj, president and chief executive officer. “Serene SC solutions will broaden the range of medical device companies able to benefit from the unmatched lubricity and durability this product family provides.”

Hydrophilic coatings continue to be a critical design input to help medical devices navigate tortuous vascular pathways. Hydrophilic coatings reduce risk of damage to blood vessel walls and allow physicians to reach distal treatment sites for procedures for improved therapeutic outcomes.

About Serene Coating Solutions
The Surmodics family of Serene hydrophilic coatings combine unmatched lubricity and durability, including dramatically improved particulate reduction. Serene hydrophilic coatings bond to a wide variety of substrates and have a proven regulatory record with leading coronary, peripheral, neurovascular and structural heart devices.

Serene coatings are applied using Surmodics’ patented Photolink® UV curing process, which covalently bonds surface treatments to substrates at ambient temperature. This flexible technology can easily be incorporated into existing manufacturing processes, and can markedly reduce production time and reagent costs compared to both thermal-curing and alternative light-activated processes.

About Surmodics Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total product solutions, Surmodics’ mission remains to improve the detection and treatment of disease by using its technology to provide solutions to difficult medical device and diagnostic challenges. Surmodics is headquartered in Eden Prairie, Minnesota.

Source: Surmodics